BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Seo YS, Kim JH, Yeon JE, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH. Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. World J Gastroenterol 2007; 13(30): 4072-4079 [PMID: 17696224 DOI: 10.3748/wjg.v13.i30.4072]
URL: https://www.wjgnet.com/1007-9327/full/v13/i30/4072.htm
Number Citing Articles
1
Shahinul Alam, Golam Azam, Golam Mustafa, Nooruddin Ahmad, Belalul Islam, Provat Kumar Podder, Mobin Khan. Pretreatment and on-treatment predictors of viral breakthrough in lamivudine therapy for chronic hepatitis BHepatology International 2008; 2(4): 494 doi: 10.1007/s12072-008-9095-9
2
James Fung, Ching-Lung Lai, John Yuen, Charles Cheng, Ringo Wu, Danny Ka-Ho Wong, Wai-Kay Seto, Ivan Fan-Ngai Hung, Man-Fung Yuen. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 YearsHepatology 2011; 53(4): 1148 doi: 10.1002/hep.24192
3
Dong Hyun Kim, Jong Won Choi, Jeong Hun Seo, Yong Suk Cho, Sun Young Won, Byung Kyu Park, Han Ho Jeon, Sang Yun Shin, Chun Kyon Lee. Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNAYonsei Medical Journal 2017; 58(3): 552 doi: 10.3349/ymj.2017.58.3.552